Note: This document contains side effect information about rilonacept. Some dosage forms listed on this page may not apply to the brand name Arcalyst.
Summary
Common side effects of Arcalyst include: upper respiratory tract infection and injection site reaction. Continue reading for a comprehensive list of adverse effects.
Applies to rilonacept: subcutaneous powder for solution.
Serious side effects of Arcalyst
Along with its needed effects, rilonacept (the active ingredient contained in Arcalyst) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking rilonacept:
More common
- Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at site
- body aches or pain
- chills
- cough
- difficulty in breathing
- ear congestion
- fever
- headache
- loss of voice
- runny or stuffy nose
- sneezing
- sore throat
- unusual tiredness or weakness
Less common
- Bladder pain
- bloody or cloudy urine
- diarrhea
- difficult, burning, or painful urination
- frequent urge to urinate
- lower back or side pain
- stomach discomfort or pain
Incidence not known
- Bloody or black, tarry stools
- constipation
- cough producing mucus
- lower back or side pain
- pain or tenderness around eyes and cheekbones
- painful or difficult urination
- severe stomach pain
- tenderness
- tightness of chest
- trouble breathing
- vomiting of blood or material that looks like coffee grounds
Other side effects of Arcalyst
Some side effects of rilonacept may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
For Healthcare Professionals
Applies to rilonacept: subcutaneous powder for injection.
Local
In patients with Cryopyrin-Associated Periodic Syndromes (CAPS), the most common and consistently reported adverse event associated with rilonacept (the active ingredient contained in Arcalyst) was injection-site reaction (ISR). The ISRs included erythema, swelling, pruritus, mass, bruising, inflammation, pain, edema, dermatitis, discomfort, urticaria, vesicles, warmth, and hemorrhage. Most injection-site reactions lasted for one to two days. No ISRs were assessed as severe, and no patient discontinued study participation due to an ISR.[Ref]
Very common (10% or more): Injection site reactions (e.g., erythema, swelling, pruritus, mass, bruising, inflammation, pain, edema, dermatitis, discomfort, urticaria, vesicles, warmth, hemorrhage) (48%)[Ref]
Immunologic
Very common (10% or more): Infection (34%)[Ref]
One subject receiving rilonacept for an unapproved indication developed an infection in his olecranon bursa with Mycobacterium intracellulare. The patient was on chronic glucocorticoid treatment. The infection occurred after an intraarticular glucocorticoid injection into the bursa with subsequent local exposure to a suspected source of mycobacteria. The patient recovered after the administration of the appropriate antimicrobial therapy.
A patient treated for another unapproved indication developed bronchitis/sinusitis, which resulted in hospitalization.
One patient died in an open-label study of CAPS from Streptococcus pneumoniae meningitis.[Ref]
Respiratory
Very common (10% or more): Upper respiratory tract infection (26%)
Common (1% to 10%): Sinusitis, cough[Ref]
Nervous system
Common (1% to 10%): Hypoesthesia[Ref]
Gastrointestinal
Common (1% to 10%): Nausea, diarrhea, stomach disorder[Ref]
Hematologic
The patient did not experience any infection associated with the neutropenia.
Physicians should monitor the lipid profiles of their patients (for example after 2 to 3 months) and consider lipid-lowering therapies as needed based upon cardiovascular risk factors and current guidelines.[Ref]
Frequency not reported: Neutropenia[Ref]
Genitourinary
Common (1% to 10%): Urinary tract infection[Ref]
Hypersensitivity
Rare (less than 0.1%): Hypersensitivity[Ref]
Metabolic
Frequency not reported: Increased mean total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides (in patients with CAPS)[Ref]
General
The most commonly reported adverse reaction is injection-site reaction (ISR). The next most commonly reported adverse reaction is upper respiratory infection.[Ref]
